Why the study?
Does diabetes compensation by various classes of antihyperglycemic agents improve endovascular intervention outcomes in patients with type 2 diabetes mellitus?
Does diabetes compensation by various classes of antihyperglycemic agents improve endovascular intervention outcomes in patients with type 2 diabetes mellitus?
This review discusses the potential impact of different antihyperglycemic agents on clinical outcomes following percutaneous coronary intervention in patients with type 2 diabetes.
Should not yet change post-PCI antihyperglycemic selection in T2DM; leaves open comparative outcome effects for prospective trials.
Introduction of drug-eluting stents for percutaneous coronary interventions opened novel options for treating coronary heart disease (CHD) in patients with diabetes mellitus. However, mortality and myocardial infarction rates are still higher among diabetes patients. They also require repeated revascularization of the target vessel more often than euglycemic individuals do. Current review discusses possible effects of diabetes compensation by various classes of antihyperglycemic agents on endovascular intervention outcomes.
No takes yet. Share an insight, caveat, or question.
Michurova et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: